相关实验视频

Updated: Jan 15, 2026

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

eEF2K通过循环素D1介导的PD-L1稳定促进黑色素瘤中的免疫逃避

Yijie Ren¹, Darby J Ballard¹, Anil Kumar¹

¹Department of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, Bryan, TX, United States.

Journal of immunology (Baltimore, Md. : 1950)

|October 16, 2025

概括

细胞延长因子2激酶 (eEF2K) 通过通过循环D1抑制增加PD-L1驱动黑色素瘤免疫逃避. 准这个轴可能会增强癌症免疫疗法.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

细胞延长因子2激酶 (eEF2K) 是一种应激反应的蛋白质合成调节剂,与黑色素瘤有关.
它在瘤免疫逃避和编程死亡带1 (PD-L1) 调节中的作用尚不清楚.

研究的目的:

研究eEF2K影响黑色素瘤PD-L1表达的机制.
探索针对eEF2K-Cyclin D1-PD-L1途径用于癌症免疫治疗的潜力.

主要方法:

癌症基因组图谱和癌症依赖地图数据集的分析.
同免疫沉以评估蛋白质相互作用.
用palbociclib.lib药理上抑制Cyclin D1的作用.
在小鼠和人类黑色素瘤模型中的体内研究使用流细胞计和免疫组织化学.

主要成果:

高的eEF2K表达与高的PD-L1和较差的黑色素瘤患者结局相关.
eEF2K抑制了循环D1,导致PD-L1稳定;eEF2K上调的循环D1和PD-L1.1的损失.
eEF2K与Cyclin D1.1发生了物理相互作用.
抑制Cyclin D1或eEF2K降低了PD-L1,增强了CD8+T细胞透,并改善了抗瘤免疫力.

结论:

eEF2K通过抑制环素D1稳定PD-L1,促进黑色素瘤免疫逃避.
eEF2K-Cyclin D1-PD-L1轴是一个潜在的治疗点,可以增强抗黑色素瘤免疫反应和检查点阻塞的有效性.

关键词:

CD8+ T 细胞 CD8+ T 细胞 eEF2K是什么意思免疫逃避免疫逃避免疫疗法免疫疗法黑色素瘤是一种黑色素瘤.

更多相关视频

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Positive Regulator Molecules

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.